Chronic hepatitis C virus (HCV) infection is a leading cause of liver cirrhosis and hepatocellular carcinoma (HCC) worldwide. The HCV capside core is a multifunctional protein with regulatory functions that aects transcription and cell growth in vitro and in vivo. Here, we show that both HCV genotype 1a and 3 core proteins activate MEK1 and Erk1/2 MAP kinases and that the costitutive expression of the HCV core results in a high basal activity of Raf1 and MAP/kinase/ kinase, as determined by endogenous Raf1 in vitro kinase assay and immunodetection of hyperphosphorylated Erk1 and Erk2 even after a serum starvation. Moreover, the activation of both Erk1/2 and the downstream transcription factor Elk-1 in response to the mitogenic stimulus EGF is signi®cantly prolonged. The sustained response to EGF in cells expressing the HCV core occurs despite a normal induction of the MAP phosphatases MKP regulatory feedback and is likely due to the costitutive activation of Raf-1 activity. The ability of HCV core proteins to directly activate the MAP kinase cascade and to prolong its activity in response to mitogenic stimuli may contribute to the neoplastic transformation of HCV infected liver cells.
Hepatitis C virus (HCV) is, worldwide, the main cause of chronic hepatitis, which often leads to liver cirrhosis and hepatocellular carcinoma (HCC). The HCV capside core protein, besides its essential role in the virus morphogenesis, also modulates many cellular functions (De Francesco, 1999) . HCV core forms homo-multimers, binds RNA, associates with the endoplasmic reticulum and has been shown to interact with several cytoplasmic and nuclear proteins, incuding apolipoprotein II, lymphotoxin-b and TNF-a type 1 receptors, putative RNA helicases and nuclear ribonucleoprotein K (Barba et al., 1997, Mamiya and Worman, 1999; You et al., 1999; De Francesco, 1999) . The functional consequences of these interactions are not well de®ned. HCV core has been shown to regulate transcription, to modulate cell susceptibility to many apoptotic stimuli, to transform rodent ®broblasts and to immortalize primary hepatocytes (Colombo, 1999; Hayashi et al., 1999; Jin et al., 2000; Lu et al., 1999; Ray et al., 2000) . More interestingly, liver expression of HCV core in transgenic mice results in early steatosis (Moriya et al., 1997) and late HCC development (Moriya et al., 1998) . A potential link between modulation of transcription and cell proliferation is provided by the reported ability of HCV core to activate the ERK/SRE signaling pathway in rodent ®broblasts (Tsuchihara et al., 1999) , in human epithelial transformed cell lines (Shrivastava et al., 1998) and in a hepatoblastoma cell line Hayashi et al., 2000) . Indeed, HCV core has been shown to bind 14-3-3 proteins and to activate Raf-1 . The extracellular signal-regulated kinases (ERKs) signaling cascade is one of the evolutionarily conserved family of mitogenactivated protein (MAP) kinases that play an important role in the regulation of growth, apoptosis and dierentiation (Garrington and Johnson, 1999) . The p44 Erk1 and p42 Erk2 MAP kinases are activated by threonine 202 and tyrosine 204 residues phosphorilation by the upstream MAP kinase/kinases MEK1/2 which in turn are activated by the MAP/kinase/kinase/ kinase cRaf1 (Garrington and Johnson, 1999) . The activation of Erk1/2 MAPKs in response to mitogenic stimuli is generally short-lived due to the induction of a number of feedback inhibitory pathways, including the upregulation of members of the dual speci®city MAP kinase phosphatases (MKP) family that inactivate the MAPK cascade at the level of the MAP kinases (Schaeer and Weber, 1999) . MKP-1 phosphatase levels are rapidly induced after ERK1/2 activation both by transcriptional activation and by ERK1/2-phosphorylation dependent protein stabilization (Brondello et al., 1999) . These mechanisms ensure a proper termination of the response to mitogens and the maintenance of cellular homeostasis. In this study we further investigate the role of HCV core in the regulation of the MAP kinases cascade and, in particular, whether and how HCV core may aect the kinetics of the Raf/MEK/Erk pathway activation in response to mitogens.
We ®rst con®rmed the ability of wild type genotype la HCV core protein to activate the endogenous Erk1/2 MAPKs and extended this observation to genotype 3 HCV core. As shown in Figure 1a , bottom panel, cell extracts from human kidney embryo 293 cells transiently transfected with the pCDNA3HA-C2-WT(1a) and pCDNA3HA-C2-WT(3) plasmids express HA-tagged core proteins of the expected size. Using an antiphospho-Erk1/2 MAP Kinases antibody (New England Biolabs), that speci®cally recognizes activated Erk1/ Erk2, we showed that HCV core type 1 activates endogenous ERKs (Figure 1a , top panel, lane 3), whereas the pCDNA3-HA empty vector and the pCDNA3-GFP expression vector (Figure 1a , top panel, lanes 1 and 2) have no eect. Although it has been proposed that HCV genotypes may have a dierent impact on the natural history of the infection and on the risk of HCC development (Bruno et al., 1997) we observed that type 3 HCV core activates at the same extent endogenous Erk1/2 ( Figure 1a , top panel, lane 4).
Figure 1 HCV core proteins activate the Raf1-MEK1/2-Erk1/2 pathway in mammalian epithelial cells. (a) HCV genotype 1a and 3 wild type core proteins (aa. 1 ± 191) activate the endogenous Erk1/2 kinases. Human kidney embryo 293 cells were transfected with 1 mg of the HCV expression plasmids pCDNA3HA-C2-WT(1a), pCDNA3HA-C2-WT(3) (lanes 3 and 4) and the control plasmids pCDNA3HA and pCDNA3-GFP (lanes 1 and 2) using the Lipofectamine Plus reagent (Life Technology). Cell extracts were prepared 36 h after transfection and hyperphosphorylated active p44 Erk1 and p42 Erk2 were immunodetected using a speci®c antiphospho-Erk1/2 antibody (New England Biolabs) (top panel). The same immunoblot was also probed with an anti-total-Erk1/2 antibody (middle panel). The expression of the dierent HA-tagged wild type core proteins was checked by immunoblotting using a rabbit polyclonal anti-HA antibody (Santa Cruz Biotechnology) (bottom panel). (b) Polyclonal cell lines obtained by pooling of individual clones of transfected and geneticin-selected CCL13/Chang cells stably express the wild type genotype 1a and 3 core proteins. Cell lysates (400 mg) were subjected to sequential anti-HA immunoprecipitation and anti-HA immunoblotting (top panel, lanes 2 and 3). An anti b-actin immunoblot was performed on the cell extracts prior to immunoprecipitation to show protein content (bottom panel). (c) HCV core expressing cells keep activated Erk1/2 after a prolonged starvation period. Control CCL13-HA polyclonal cell line and CCL13-C-WT(1a) cells are mantained in 0.1% FCS for 48 h. Cell extract were subjected to immunoblotting with both the anti-phospho-Erk1/2 antibody (top panels) and the anti-total-Erk1/2 antibody (bottom panels). (d) Chronic HCV core expression activates the Raf1 kinase. The in vitro kinase assays were performed using recombinant MEK1 (Santa Cruz Biotechnology) as a substrate and Raf1 immunoprecipitated from cell extracts (500 mg) of control CCL13-HA polyclonal cell line and CCL13-C-WT(1a) cells mantained for 48 h in 0.1% FCS. The levels of immunoprecipitated Raf1 (polyclonal anti-Raf1 from Santa Cruz Biotechnology) are shown in the bottom panel. (e) Core expressing cells display a higher growth rate in low serum. Control CCL13-HA cells and CCL13-C-WT(1a) polyclonal cell line were plated at 5610 4 cells per 35 mm dish and cultured in 0.1% FCS containing medium. At 1, 2 and 3 days after plating, three plates for each polyclonal population were trypsinized and counted.`Control' was the number of cells at the baseline. The data show the means of three independent experiments. It is important to note that in CCL13/Chang cells p53 is functionally inactive (Bergametti et al., 1999) and that HCV core expression in these as well as in Hep3B p53-de®cient cells does not result in any detectable growth arrest/apoptosis in colony formation assays (data not shown; Lu et al., 1999) Oncogene
To characterize more in detail the eects on ERK signaling of a low level HCV core chronic expression, a situation that would be more similar to what is expected to happen in vivo, we generated CCL13/ Chang-derived polyclonal cell lines stably expressing the dierent HCV core proteins described above (CCL13-HA, CCL13-C-WT(1a), CCL13-C-WT(3)). HCV core proteins expression levels were assessed by sequential immunoprecipitation and immunoblotting using an anti-HA antiserum (Figure 1b, top panel) . Polyclonal cell lines expressing HCV core proteins do not show a signi®cantly higher level of activated Erk1/ 2 and do not grow faster when cultured in high serum containing medium (data not shown). However, dierently from the control CCL13-HA cells, the core expressing cells keep a persistent low level of activated Erk1/2 (Figure 1c, top panel, lane 4) and display substantial Raf1 activity, as shown by in vitro kinase assay of immunoprecipitated Raf1 and recombinant MEK-1 as a substrate (Figure 1d , top panel, lane 2), even after a prolonged starvation period. HCV core expressing cells also display a slight but consistent higher growth rate in low-serum (Figure 1e ).
These observations indicate that HCV core chronic expression may result in a constitutive activation of Erk1/2 and prompted us to investigate whether HCV core proteins may also alter the kinetics and the extent of Erk1/2 activation after the triggering of mitogenic signaling by the physiological stimulus Epidermal Growth Factor (EGF). To this aim the dierent polyclonal cell lines were starved for 48 h and then stimulated with 5 ng/ml of EGF (Chemicon International, Inc.). HCV core type 1a and type 3 expressing cells display, as compared to the control polyclonal cell line, a prolonged Erk1/2 activation after EGF treatment (Figure 2a ,b and data not shown). Erk1/2 activation correlates with a sustained accumulation of phospho-activated Elk1 (Figure 2c ), a well known downstream target of Erk1/2 and a component of the Ternary Complex Factor (TCF) that activates transcription from the Serum Responsive Element (SRE) present in the c-Fos promoter (Garrington and Johnson, 1999) . The prolonged activation of ERKs in our cells is not due to a de®cient induction of MAPKs negative feedback loops. Indeed, as shown in Figure  2d , HCV core expressing cells also display a sustained accumulation of the MKP1 phosphatase, as detected by immunoblotting using an anti-MKP1 antibody (Santa Cruz Antibodies, Inc).
To explain the lack of Erk1/2 downregulation in the presence of a normal accumulation of MKP-1 protein, we next investigated whether HCV core may interfere with the phosphatase activity of MKPs on Erk1/2. To this aim both control and HCV core expressing cells were ®rst starved and then EGF stimulated for 30 min to activate Erk1/2. After the removal of EGF and the addition of the speci®c MEK-1 inhibitor PD98059, to avoid further activation of Erk1/2 by their upstream kinases, the levels of phosphorylated ERK1/2 were assessed at the indicated times (Figure 2e ). If HCV core interferes with Erk1/2 dephosphorylation by MKPs the HCV core expressing cells treated with PD98059 should display higher levels of phosphoErk1/2, as compared to the control cell line. As shown in Figure 2e , EGF treatment results in the expected Erk1/2 activation in both the control and the HCV core expressing polyclonal cell lines (Figure 2e, lanes 3  and 4) . However, after PD98059 treatment, HCV core expressing cells (Figure 2e, lanes 8 and 12) and control cells (Figure 2e , lanes 6 and 10) display comparable levels of activated Erk1/2. This result indicates that HCV core does not signi®cantly aect MAPK phosphatases function and suggests that upstream activators, including MEK-1 or Raf1, directly or indirectly activated by HCV core, likely play a major role for the observed sustained activation of ERK. Indeed, our HCV core expressing cell lines display a costitutive Raf1 activity even under starvation conditions (Figure 1d, top panel, lanes 1 and 2) and HCV core has been shown to bind the 14-4-3e protein both in vitro and in vivo and to activate the Raf1 kinase . The role of 14-3-3 in the regulation of Raf1 is complex (Morrison and Cutler 1997 ). 14-3-3 is required for maintaining Raf1 in an inactive conformation but, in response to signaling events and Ras activation, 14-3-3 is displaced from Ser 259 and is free to bind the higher anity Ser 621 residue in the Raf1 kinase domain. This latter interaction is important to facilitate and stabilize the active Raf1 conformation and protects Raf1 from being inactivated by phoshatases. Although the mechanism by which HCV core/14-3-3 interaction promotes activation of Raf1 is still unclear , our current understanding of 14-3-3 functions in Raf1 regulation may also account for HCV core ability to prolong the activation of the Raf1-MEK-Erk1/2 pathway in response to EGF.
In conclusion we show that constitutive HCV core protein expression in mammalian epithelial cells results in both a high basal activity of Raf1 and MAP/kinase/ kinase, as determined by endogenous Raf1 in vitro kinase assay and immunodetection of hyperphosphorylated Erk1/2, and, even more interestingly, a prolonged Erk1/2 response to mitogenic stimuli such as EGF. Several studies have demonstrated that HCC development and progression is associated with activation of the Raf1/MAP kinase pathway in humans (Ito et al., 1998; Schmidt et al., 1997) and rodents (Kalkuhl et al., 1998; McKillop et al., 1997) . The MAP kinase cascade is also activated by the hepatitis B virus regulatory protein HBx (Doria et al., 1995; Natoli et al., 1994) , through the activation of the Scr family of tyrosine kinases (Klein and Schneider, 1997) , suggesting that signaling to the ERK subset of MAP kinases may represent a common mechanism for HBV and HCV proteins to modulate cell proliferation. This is particularly relevant in view of the recent demonstration that many HCV chronically infected patients also harbor an`occult' HBV coinfection (Cacciola et al., 1999; Shibata et al., 1999; Tamori et al., 1999) and that HBV-HCV co-infected cirrhotic patients seem to have an increased risk to develop HCC over time (Donato et al., 1998) . Moreover, Hayashi et al. (2000) have recently shown that Erk1/2 activation by HCV core is enhanced by TPA, that activates Raf1 through PKC and the phosphorylation of Ser 497 and Ser 499 in the Raf1 kinase domain, suggesting that HCV core may act synergistically with other stimuli that activate Raf1 with a dierent mechanism. The ability of HCV core proteins to activate the MAP kinase cascade may contribute, in concert with its ability to protect cells from various apoptotic stimuli (De Francesco, 1999) and with other genetic or environmental factors (Hayashi et al., 1999) , to the neoplastic transformation of HCV infected liver cells. Polyclonal cell lines expressing wild type HCV core type 1a display a prolonged activation of Erk1/2 after EGF stimulation. Cells were mantained in 0.1% FCS containing medium for 48 h and then treated for the indicated times with 5 ng/ml of EGF (Chemicon International, Inc.). Hyperphosphorylated active Erk1/2 were detected by immunoblot using the speci®c anti-phospho-Erk1/2 antibody (New England Biolabs) (top panels). Total Erk1/2 was visualized by reprobing ®lters with a rabbit polyclonal anti-totalErk1/2 (New England Biolabs) (bottom panels). (b) Relative accumulation of activated Erk1/2 after EGF treatment (fold induction) shown are the means of duplicate determinations from three independent experiments. (c) The prolonged Erk1/2 response to EGF in HCV type 1a core protein expressing cells results in a sustained accumulation of phospho-activated-Elk1. Control CCL13-HA cells and CCL13-C-WT(1a) polyclonal cell line were treated as in (a) and cell lysates prepared at the indicated times were subjected to immunoblot using an anti-phospho-Elk1 antibody (New England Biolabs) (top panel). The same immunoblot was also probed with an anti-total-Elk1 antibody (bottom panel). (d) The MAP kinase phosphatase MKP1 is normally induced in HCV core expressing cells in response to EGF and Erk1/2 activation. Control CCL13-HA cells and CCL13-C-WT(1a) polyclonal cell line were treated as in (a) and cell lysates prepared at the indicated times were subjected to immunoblot using an anti-MKP1 antibody (Santa Cruz Biotechnology) (top panel). An anti b-actin immunoblot was performed to show protein content (bottom panel). (e) HCV core does not interfere with MKPs phosphatase activity on endogenous Erk1/2 activated in response to EGF. Control CCL13-HA polyclonal cell line and CCL13-C-WT(1a) cells were starved, EGF-stimulated (5 ng/ml) for 30 min and then treated with the MEK-1 speci®c inhibitor PD98059 (40 mM) (New England Biolabs). Cell extracts prepared at the indicated times were used to detect phosphoactivated Erk1/2 and total Erk1/2 by immunoblotting
